Scinai Immunotherapeutics (SCNI) director reports ADS and option holdings

Rhea-AI Filing Summary

Scinai Immunotherapeutics Ltd. director Raviv Adi filed an initial ownership report showing direct holdings in American Depositary Shares and stock options linked to the company’s Ordinary Shares. This filing does not report any new purchases or sales, only existing positions.

The report lists 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares with no expiration. It also shows several stock option grants over Ordinary Shares at exercise prices of $0.005 and $0.0004 per share, vesting in scheduled installments through August 24, 2027 and December 22, 2026, subject to continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Raviv Adi

(Last) (First) (Middle)

C/O SCINAI IMMUNOTHERAPEUTICS LTD.

JERUSALEM BIOPARK, 2ND FLOOR

(Street)

JERUSALEM 9112002

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Scinai Immunotherapeutics Ltd. [ SCNI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
American Depositary Shares	(1)	(1)	Ordinary shares, no par value per share ("Ordinary Shares")(2)	200,000	(1)	D
Stock Option (right to buy)	(3)	08/24/2033	Ordinary Shares	1,720,000	$0.005	D
Stock Option (right to buy)	(4)	08/24/2033	Ordinary Shares	8,000,000	$0.005	D
Stock Option (right to buy)	(5)	12/22/2035	Ordinary Shares	48,200,000	$0.0004	D

Explanation of Responses:

1. Represents 50 American Depositary Shares, which are convertible at any time into 200,000 Ordinary Shares, at the holder's election and have no expiration date.

2. The Ordinary Shares are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.

3. The option vests in one installment on August 24, 2027, subject to the Reporting Person's continued service through such date.

4. The option vests in three equal annual installments commencing August 24, 2024, subject to the Reporting Person's continued service through such dates.

5. The option vests in three equal annual installments commencing December 22, 2026, subject to the Reporting Person's continued service through such dates.

Remarks:

Exhibit 24 - Power of Attorney.

	/s/ Amir Reichman, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Form 3 filing for Scinai Immunotherapeutics (SCNI) show for Raviv Adi?

The Form 3 reports Raviv Adi’s existing holdings, not new trades. It lists American Depositary Shares and multiple stock option grants over Ordinary Shares, establishing his baseline ownership as a director of Scinai Immunotherapeutics Ltd.

How many Scinai Immunotherapeutics (SCNI) shares are tied to Raviv Adi’s American Depositary Shares?

The filing shows 50 American Depositary Shares, convertible into 200,000 Ordinary Shares. Each American Depositary Share currently represents 4,000 Ordinary Shares, and these can be converted at the holder’s election with no expiration date mentioned.

What stock options over Scinai Immunotherapeutics (SCNI) Ordinary Shares does Raviv Adi hold?

Raviv Adi holds several stock option awards over Ordinary Shares with exercise prices of $0.005 and $0.0004. These options cover millions of underlying Ordinary Shares and provide the right to buy shares at those fixed prices, subject to vesting schedules.

When do Raviv Adi’s Scinai Immunotherapeutics (SCNI) stock options vest?

The options vest based on continued service. One grant vests in a single installment on August 24, 2027, while others vest in three equal annual installments starting August 24, 2024 and December 22, 2026, as long as service conditions are met.

Does the Scinai Immunotherapeutics (SCNI) Form 3 show Raviv Adi buying or selling shares?

The Form 3 does not show any buying or selling activity. It is an initial ownership report, so it simply records Raviv Adi’s existing American Depositary Shares and option positions rather than reporting new market transactions.